BDBM50239497 CHEMBL4084228::US10329302, Example 271::US10793579, Example 271::US11702424, Example 271

SMILES [H][C@]12[C@H](C)[C@@]1([H])C(=O)N[C@@H]2COc1nccc2cc(C(N)=O)c(OC)cc12

InChI Key InChIKey=ZMKZEHYXGVIWQY-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 50239497   

TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 2.40nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 2.40nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 2.40nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 2.40nMAssay Description:Inhibition of N-terminal His6-tagged human full length IRAK4 preincubated for 20 mins followed by biotinylated-AGAGRDKYKTLRQIR substrate addition in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/22/2019
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 2.40nMAssay Description:Inhibition of full-length IRAK4 (unknown origin) in presence of ATP by DELFIA assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/16/2024
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 52nMAssay Description:Inhibition of IRAK4 in human PBMC cells assessed as reduction in R848-stimulated TNF-alpha productionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/16/2024
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Pfizer

US Patent
LigandPNGBDBM50239497(CHEMBL4084228 | US10329302, Example 271 | US107935...)
Affinity DataIC50: 52nMAssay Description:Inhibition of IRAK4 in human PBMC assessed as reduction in R848-stimulated TNF alpha production after 3 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/22/2019
Entry Details Article
PubMed